The value of Pathology Technology
The power of our industry supports over 70% of clinical decision making and is the driver of healthcare strategies and outcomes.
Our member’s innovative tests and technology are found in public and private pathology laboratories and increasingly at the point-of-care, including for infectious diseases, diabetes, COVID rapid antigen tests (RATs), and home pregnancy tests.

History of PTA
Formed in July 2009, Pathology Technology Australia represents Australian manufacturers, multi-national and local distributors of in vitro diagnostics (IVDs), as well as regulatory consultants.
Our industry supplies products valued around AUD $1 billion a year and employs over 2,500 people.
The role of PTA
PTA undertakes its role via:
- Facilitating the growth and development of industry professionals, developing and disseminating information on IVDs, and providing education and training for the sector and adjacent professions.
- Active involvement in regulatory, technical, reimbursement and industry development issues and discussions.
- Representing the interests of members to the Commonwealth, State, and Territory governments and legislatures, plus other institutions within Australia.
- Promoting the marketing of quality IVDs.
- Encouraging the manufacture and export of Australian made IVDs.
- Supporting and encouraging Australian research and development.
- Improving community awareness and understanding of the IVDs industry.
- Acting as sector voice in media, press releases, and government consultative processes.
- Providing a forum to discuss issues related to improving patient and clinician access to IVDs.

PTA Code of Practice
Members adhere to the Pathology Technology Industry Code of Practice, engaging in ethical corporate conduct with healthcare professionals and organizations.
The Constitution of Pathology Technology Australia is available here.